The estimated Net Worth of Lawrence S Olanoff is at least $1.3 Million dollars as of 10 June 2020. Lawrence Olanoff owns over 11,350 units of Ironwood Pharmaceuticals Inc stock worth over $298,536 and over the last 10 years he sold IRWD stock worth over $711,232. In addition, he makes $289,317 as Independent Director at Ironwood Pharmaceuticals Inc.
Lawrence has made over 18 trades of the Ironwood Pharmaceuticals Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 11,350 units of IRWD stock worth $114,181 on 10 June 2020.
The largest trade he's ever made was selling 11,350 units of Ironwood Pharmaceuticals Inc stock on 10 June 2020 worth over $114,181. On average, Lawrence trades about 1,699 units every 56 days since 2015. As of 10 June 2020 he still owns at least 68,629 units of Ironwood Pharmaceuticals Inc stock.
You can see the complete history of Lawrence Olanoff stock trades at the bottom of the page.
Dr. Lawrence S. Olanoff M.D., Ph.D. serves as Independent Director of the Company. is an Independent Director of the Company. Dr. Olanoff most recently served as chief operating officer for Forest Laboratories, Inc. (acquired by Allergan plc) from October 2006 to December 2010. Dr. Olanoff also served as a director of Forest from October 2006 to July 2014. From July 2005 to October 2006, Dr. Olanoff was president and chief executive officer and a director at Celsion Corporation. He also served as executive vice president and chief scientific officer of Forest from 1995 to 2005. Prior to joining Forest in 1995, Dr. Olanoff served as senior vice president of clinical research and development at Sandoz Pharmaceutical Corporation (now a division of the Novartis Group) and at the Upjohn Company in a number of positions including corporate vice president of clinical development and medical affairs. In addition, he is currently an adjunct assistant professor and special advisor to the president for corporate relations at the Medical University of South Carolina (MUSC), an ex-officio director of the MUSC Foundation for Research Development, chairman of the board of Mitochondria in Motion, a biopharmaceutical company and a board member of the Clinical Biotechnology Research Institute at Roper St. Francis Hospital, the Westedge Project, and the Zucker Institute for Applied Neurosciences, and a former board member of Axovant Sciences Ltd. and Celsion Corporation. Dr. Olanoff received his Ph.D. in biomedical engineering and M.D. degree from Case Western Reserve University.
As the Independent Director of Ironwood Pharmaceuticals Inc, the total compensation of Lawrence Olanoff at Ironwood Pharmaceuticals Inc is $289,317. There are 13 executives at Ironwood Pharmaceuticals Inc getting paid more, with Mark Mallon having the highest compensation of $10,068,800.
Lawrence Olanoff is 68, he's been the Independent Director of Ironwood Pharmaceuticals Inc since 2015. There are 1 older and 18 younger executives at Ironwood Pharmaceuticals Inc. The oldest executive at Ironwood Pharmaceuticals Inc is Edward Owens, 73, who is the Independent Director.
Lawrence's mailing address filed with the SEC is C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON, MA, 02110.
Over the last 15 years, insiders at Ironwood Pharmaceuticals Inc have traded over $83,928,361 worth of Ironwood Pharmaceuticals Inc stock and bought 2,478,676 units worth $24,100,589 . The most active insiders traders include Llc Fmr, Bryan E Roberts und Alexander J Denner. On average, Ironwood Pharmaceuticals Inc executives and independent directors trade stock every 19 days with the average trade being worth of $239,611. The most recent stock trade was executed by Minardo John on 12 August 2024, trading 9,910 units of IRWD stock currently worth $42,316.
ironwood pharmaceuticals (nasdaq: irwd) is focused on creating medicines that make a difference for patients, building value to earn the continued support of our fellow shareholders, and empowering our passionate team to keep doing these two things again and again as we continue to build a leading gastrointestinal therapeutics company. we discovered, developed and are commercializing a medicine for the treatment of adults suffering from irritable bowel syndrome with constipation (ibs-c) or chronic idiopathic constipation (cic). we are also developing a rich pipeline of programs seeking to address patient needs across the upper and lower gastrointestinal tract. our pipeline priorities include exploring further opportunities for our lead medicine, as well as leveraging our therapeutic expertise in gastrointestinal disorders and our pharmacologic expertise in guanylate cyclases to advance multiple investigational medicines. ironwood was founded in 1998 out of the whitehead institute for b
Ironwood Pharmaceuticals Inc executives and other stock owners filed with the SEC include: